Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

Launched by UNIVERSITY OF CHICAGO · Feb 12, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether elderly men with prostate cancer can safely stop their hormone treatment earlier than usual. The treatment being studied is called LHRH agonist therapy, which helps lower testosterone levels that can fuel prostate cancer growth. Researchers believe that after being on this treatment for a long time, many older patients may no longer need it because their testosterone levels have become very low and stable. Throughout the study, participants will have their testosterone levels checked regularly to monitor their health.

To participate in this study, men must be at least 70 years old and have been receiving LHRH agonist therapy for more than three years. They should also have a low baseline testosterone level and be able to understand and agree to the study requirements. Importantly, this trial is not yet recruiting participants, but it aims to provide valuable insights into the treatment needs of older men with prostate cancer. If you or someone you know fits these criteria, this study could offer a chance to explore the possibility of reducing or stopping treatment safely.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Prostate cancer with \>3 years of LHRH agonist therapy.
• • Age ≥70 years.
• • ECOG performance status ≤2
• • Baseline testosterone of \< 20 ng/ml
• • No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable).
• • Ability to understand and sign informed consent.
• Exclusion Criteria:
• • none